Drug strategy

Despite the presence of the more lipophilic side-chain in 18, compared to the glycerol side-chain of 12, a pro-drug strategy was necessary to achieve sufficient oral bioavailabUity. Thus, the ethyl ester pro-drug form of 18, oseltamivir (GS 4104,... 

Hall W, Solowij N and Lemon J (1994). The Health and Psychological Consequences of Cannabis Use (National Drug Strategy Monograph Series No. 25). Australian Government Publishing Service, Canberra. 

Source. Casidy R, Frey R. Drug Strategies to Target HIV Enzyme Kinetics and Enzyme Inhibitors, Washington University. http //wunmr.wustl.edu/EduDev/Lab I itorials/F[IV/ DrugStrategies.html [accessed May 21,2003]. 

The President s National Drug Strategy, Press Release, (2002, February 12), Office of the White House Press Secretary, Retrieved April 9, 2004 from http //www.whitehouse.gov/news/releases/2002/02/20020212-2.html... 

Clinical trials with monotherapy pro-drug strategies are in progress, but have not yet been evaluated. 

Case JP. Old and new drugs used in rheumatoid arthritis A historical perspective. Part 2 The newer drugs and drug strategies. Am J Ther 2001 8 163-179. 

J. Knoll (1982). Selective inhibition of B-type monoamine oxidase in brain a drug strategy to improve quality of life in senescence. In J. A. Keverling Buisman (Ed.). Strategy in Drug Research. Amsterdam Elsevier. 

Source AIFIW, 2004 National Drug Strategy - Flousehold Survey. 

Source Australian Institute of Health and Welfare, The 2004 National Drug Strategy Household Survey. 

The Cancer Council Victoria, Report for Drug Strategy Branch, Dept of Health and Ageing, Government of Australia, Australian secondary school students use of over-the-counter and illicit substances in 2005, June 2006... 

Source Australian Institute for Health and Welfare (AIHW), 2004 National Drug Strategy - Household Survey 2004, Canberra 2005. 

Adessi, C., and Soto, C. (2002) Converting a peptide into drug strategies to improve stability and bioavailability. Curr. Med. Chem. 9, 963-978. 

Crommelin, D.J.A. and Storm, G. (2000) Stealth Therapeutic Systems Rationale and Strategies. In Targeting of Drugs Strategies for Stealth Therapeutic Systems (Gregoriadis, G., ed.). Plenum Press, New York, In Press. 

Numerous matters related to public health and biomedical sciences can be the subject of Recommendations but without compulsory nature contrary to international regulations. WHO Recommendations may be endorsed by the WHA under article 23 or by the Executive Board and issued as resolutions (e.g., WHA 52.19 Resolution on the revised drug strategy, 1999). 

As the described age-dependent chain of events can be deduced to well-defined biochemical lesions, the chances of developing a new drug strategy for counteracting or possibly even preventing the adverse consequences of the age-related decrease of the catecholaminergic tone in the brain are fair. 

---